Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: a study against active, dormant and resistant tuberculosis

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Jonnalagadda P SrideviDharmarajan Sriram

Abstract

Mycobacterium tuberculosis (Mtb) topoisomerase I (Topo I), involved in the relaxation of negatively supercoiled DNA, plays an important role in the viability of pathogen Mtb. Being one of the most significant enzymes; it also takes part in crucial biological pathways such as transcription and replication of the pathogen. The present study aims at the development of Mtb Topo I 3D protein structure which in turn was employed for the virtual screening of compound libraries in a process of identification of a hit molecule. The identified hit, hydroxycamptothecin, was active at 6.25 μM which was further derivatized synthetically into fifteen novel analogues. Among these, four compounds (3b, 3g, 3h and 3l) emerged to be active displaying IC50 values ranging from 2.9 to 9.3 μM against Mtb Topo I and were non-cytotoxic at 25 μM. These four compounds also proved their efficacy when tested against active, dormant and resistant forms of Mtb. The most potent inhibitor 3b was screened for in vivo anti-mycobacterial activity using zebrafish model and was found to be more effective when compared to first line anti-tubercular drugs, isoniazid and rifampicin. The binding affinity of this compound towards Mtb Topo I was analyzed by differential ...Continue Reading

References

Oct 5, 1990·Journal of Molecular Biology·S F AltschulD J Lipman
Mar 19, 2004·Journal of Medicinal Chemistry·Richard A FriesnerPeter S Shenkin
Feb 27, 2008·Cellular Microbiology·David M Tobin, Lalita Ramakrishnan
Apr 24, 2010·Veterinary Microbiology·Satoko KawajiRichard J Whittington
Jul 28, 2013·Frontiers in Microbiology·Keith D Green, Sylvie Garneau-Tsodikova
Oct 24, 2013·European Journal of Medicinal Chemistry·Variam Ullas JeankumarDharmarajan Sriram
Mar 20, 2014·Biochemical and Biophysical Research Communications·Adwait Anand GodboleValakunja Nagaraja
Dec 24, 2014·Antimicrobial Agents and Chemotherapy·Adwait Anand GodboleValakunja Nagaraja
Jan 21, 2016·International Journal of Mycobacteriology·Jonnalagadda Padma SrideviDharmarajan Sriram

❮ Previous
Next ❯

Citations

Dec 15, 2015·Journal of Molecular Biology·Kemin TanYuk-Ching Tse-Dinh
Sep 2, 2015·Seminars in Immunopathology·Annemarie H Meijer
Jun 11, 2016·Future Medicinal Chemistry·Yuk-Ching Tse-Dinh
Dec 1, 2017·Frontiers in Molecular Biosciences·Michael A ReicheValerie Mizrahi
Feb 19, 2019·Microbiology·Soma MandalTanya Parish
Jun 27, 2019·Mini Reviews in Medicinal Chemistry·Gopichand GuttiSushil Kumar Singh
Sep 19, 2019·Pharmaceuticals·Giulia Oliveira TimoMauricio Homem-de-Mello
Feb 25, 2017·Microbiology Spectrum·Ben Gold, Carl Nathan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.